Eosinophilic asthma is a subtype of the larger asthma condition, constituting a specific phenotype identified by the over-production of eosinophils, a form of white blood cells, in the lungs. This subtype is an essential subset to understand as it tends to be more severe and less responsive to standard asthma treatments. This heightened severity stems from the prolonged inflammation and consequent damage to the airways, leading to a higher likelihood of hospitalization.

Foremost, comprehending the unique characteristics of eosinophilic asthma aids in identifying its distinct clinical features. One of its primary identifiers is a higher eosinophil count in the blood, sputum, and lung tissue. This count can be measured using various diagnostic tools such as blood tests, sputum tests, and bronchoscopy with biopsy.

Symptoms of eosinophilic asthma often mirror those of traditional asthma, including prolonged coughing, wheezing, shortness of breath, and difficulty in breathing. However, these symptoms tend to be persistent and resistant to standard asthma treatments such as bronchodilators and inhaled corticosteroids. Moreover, affected individuals usually experience these symptoms later in life, typically after the age of 50, and many have no previous history of asthma.

Standard asthma treatments often prove ineffective in managing eosinophilic asthma because they do not alter the progression of the disease or reduce the eosinophil levels in the airways. Advances in therapy have led to the development of biologic medications that specifically target eosinophils and other components of the immune response. Biologics such as Mepolizumab, Reslizumab, and Benralizumab have proven effective in reducing the number of eosinophils and hence, managing the symptoms of eosinophilic asthma.

The approval of these therapeutics represents a significant step forward for individuals with severe eosinophilic asthma who previously had few treatment options. This does not, however, lessen the need for further research. A deeper understanding of the underlying mechanisms of eosinophilic asthma will enhance the development of more effective treatments and perhaps, in due time, a cure.

In conclusion, eosinophilic asthma symbolizes a severe form of asthma marked by high eosinophil counts and resistance to conventional asthma medications. The advent of biologics has transformed the treatment landscape by providing targeted and effective therapies. Despite these strides, there is still a critical need to advance our comprehension and address the unmet needs within eosinophilic asthma. Hence, ongoing research towards improved diagnostic technologies and more effective therapeutic strategies remains an imperative.